Richard McConnell
Allergy & Immunology · Pantego, TXNPI 1669503363
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,691 of the $5,072 with a category attached, or 72.8%. 23 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 24.2% of the total. Reporting peaked in 2021 at $1,477 and has fallen 59.4% since, to $600 in 2025. That places this record below the midpoint for allergy & immunology clinicians in TX, where the typical reported total is $5,878.
Across 119 payments — averaging $42.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- GSK$726
- AstraZeneca$623
- Takeda Pharmaceuticals U.S.A., Inc.$610
- ADMA Biomanufacturing LLC$258
- Sanofi-aventis U.S. LLC$209
- plus $1K from 17 others
What the payments were for
- Consulting fees$1,20024%
- Food & beverage$3,69173%
- Education$1814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 3 | $1,229 |
| GSK | 30 | $726 |
| AstraZeneca | 18 | $623 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $610 |
| ADMA Biomanufacturing LLC | 2 | $258 |
| Sanofi-aventis U.S. LLC | 4 | $209 |
| Regeneron Healthcare Solutions, Inc. | 9 | $194 |
| Alk-abello, Inc | 2 | $191 |
| Pfizer | 6 | $181 |
| Grifols USA, LLC | 3 | $180 |
| CSL Behring | 2 | $113 |
| AbbVie(2 entities) | 3 | $112 |
| Biocryst US Sales Co., LLC | 3 | $97 |
| Novartis | 1 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Sanofi | 3 | $53 |
| Octapharma USA, Inc. | 1 | $33 |
| Upsher-smith Laboratories LLC | 1 | $28 |
| Pharming Healthcare, Inc. | 2 | $27 |
| Amgen | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,072 in reported general payments places this provider in the 45th percentile of 336 allergy & immunology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 20 | $78,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $36,154 |
| Zafirlukast | 35 | $2,379 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $857 |
| Prednisone | 18 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $726 | $36,15431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Pantego
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
- Serge de GolovineBellaire$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.